Implantation of implantable cardioverter defibrillators (ICD) has widely been accepted for secondary prevention of sudden cardiac death (SCD) in cardiac arrest survivors. Currently there are increasing interests in primary prevention of SCD in selected high risk patients who have not experienced cardiac arrest. Despite of extensive investigation for risk stratification， our current ability to accurately identify patients at high risk for SCD remains very poor.